ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Roche, Synlogic team for immunotherapy trial

by Lisa Jarvis
June 1, 2019 | APPEARED IN VOLUME 97, ISSUE 22

Roche and Synlogic have teamed up to test combining two immune-modulating cancer treatments: Roche’s PD-L1 checkpoint inhibitor Tecentriq and Synlogic’s SYNB1891, a strain of Escherichia coli engineered to express an agonist of STING, part of the innate immune system that drives the production of inflammatory proteins that, in turn, cause the adaptive immune system to kick into gear. Synlogic says it will ask the US Food and Drug Administration for the green light to begin human studies of SYNB1891 in the second half of this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment